

180 Opioids



REFERENCES

1. DAWN Emergency Department Publications. Drug Abuse Warning Network (DAWN). Available at <https://dawninfo.samhsa.gov/pubs/edpubs/>. Accessed March 2009.
2. Paulozzi LJ, Budnitz DS, Xi Y: Increasing deaths from opioid analgesics in the United States. *Pharmacoepidemiol Drug Saf* 15: 618, 2006.
3. Hall AJ, Logan JE, Toblin RL, et al: Patterns of abuse among unintentional pharmaceutical overdose fatalities. *JAMA* 33: 2613, 2008.
4. Bronstein AC, Spyker DA, Cantilena LR, et al: 2008 Annual report of the American Association of Poison Control Centers National Poison Data System (NPDS): 26th annual report. *Clin Toxicol (Phila)* 47: 911, 2009.
5. Madadi P, Ross CJ, Hayden MR, et al: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breast feeding: a case-control study. *Clin Pharmacol Ther* 85: 20, 2009.
6. Sporer KA: Acute heroin overdose. *Ann Intern Med* 130: 584, 1999.
7. Hoffman JR, Schriger DL, Luo JS: The empiric use of naloxone in patients with altered mental status: a reappraisal. *Ann Emerg Med* 20: 246, 1991.
8. Moeller KE, Lee KC, Kissack JC: Urine drug screening: practical guide for clinicians. *Mayo Clin Proc* 83: 66, 2008. Erratum in: *Mayo Clin Proc* 83: 851, 2008.
9. O'Malley GF, Seifert S, Heard K, et al: Olanzapine overdose mimicking opioid intoxication. *Ann Emerg Med* 34: 279, 1999.
10. Schneir AB, Vadeboncoeur TF, Offerman SR, et al: Massive OxyContin ingestion refractory to naloxone. *Ann Emerg Med* 40: 425, 2002.
11. Dowling J, Isbister GK, Kirkpatrick CM, et al: Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. *Ther Drug Monit* 30: 490, 2008.
12. Ashton H, Hassan Z: Best evidence topic report. Intranasal naloxone in suspected opioid overdose. *Emerg Med J* 23: 221, 2006.
13. Doe-Simkins M, Walley AY, Epstein A, Moyer P: Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. *Am J Public Health* 99: 788, 2009.
14. Clarke SF, Dargan PI, Jones AL: Naloxone in opioid poisoning: walking the tightrope. *Emerg Med J* 22: 612, 2005.
15. Buajordet I, Naess AC, Jacobsen D, Brørs O: Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. *Eur J Emerg Med* 11: 19, 2004.
16. Schug SA, Zech D, Grond S: Adverse effects of systemic opioid analgesics. *Drug Saf* 7: 200, 1992.
17. Christenson J, Etherington J, Grafstein E, et al: Early discharge of patients with presumed opioid overdose: development of a clinical prediction rule. *Acad Emerg Med* 7: 1110, 2000.
18. Sporer KA: Buprenorphine: a primer for emergency physicians. *Ann Emerg Med* 43: 580, 2004.
19. Hayes BD, Klein-Schwartz W, Doyon S: Toxicity of buprenorphine overdose in children. *Pediatrics* 121: 782, 2008.
20. Krantz MJ, Martin J, Stimmel B, et al: QT_c interval screening in methadone treatment. *Ann Intern Med* 150: 387, 2009.
21. Reeves RR, Burke RS: Tramadol: basic pharmacology and emerging concepts. *Drugs Today (Barc)* 44: 827, 2008.
22. WHO Expert Committee on Drug Dependence: WHO Expert Committee on Drug Dependence. *World Health Organ Tech Rep Ser* 942: 1, 2006.
23. Das PK, Warkentin DI, Hewko R, Forrest DL: Serotonin syndrome after concomitant treatment with linezolid and meperidine. *Clin Infect Dis* 46: 264, 2008.
24. Mell HK, Sztajnkrzyer MD: Clinical images in medical toxicology: heroin overdose with non-cardiogenic pulmonary edema. *Clin Toxicol (Phila)* 44: 399, 2006.
25. Sterrett C, Brownfield J, Korn CS, et al: Patterns of presentation in heroin overdose resulting in pulmonary edema. *Am J Emerg Med* 21: 32, 2003.
26. Nonpharmaceutical fentanyl-related deaths—multiple states, April 2005–March 2007. Centers for Disease Control and Prevention (CDC). *MMWR Morb Mortal Wkly Rep* 57: 793, 2008.
27. Burns RS, LeWitt PA, Ebert MH, et al: The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *N Engl J Med* 312: 1418, 1985.
28. Kosten TR, O'Connor PG: Management of drug and alcohol withdrawal. *N Engl J Med* 348: 1786, 2003.
29. Gowing L, Farrell M, Ali R, White JM: Alpha₂-adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev* 2: CD002024, 2009.
30. Hauser L, Anupindi R, Moore W: Hydroxyzine for the treatment of acute opioid withdrawal: a 20-year clinical experience. *Resid Staff Physician* 52(6): 24, 2006.
31. Pinkofsky HB, Hahn AM, Campbell FA, et al: Reduction of opioid-withdrawal symptoms with quetiapine. *J Clin Psychiatry* 66: 1285, 2005.
32. Gowing L, Ali R, White JM: Buprenorphine for the management of opioid withdrawal. *Cochrane Database Syst Rev* 3: CD002025, 2009.

USEFUL WEB RESOURCES

- Drug Abuse Warning Network—<http://dawninfo.samhsa.gov/>
 American Association of Poison Control Centers—<http://www.aapcc.org/DNN/>
 American Academy of Clinical Toxicology—<http://www.clintox.org/index.cfm>
 European Association of Poisons Centres and Clinical Toxicologists—<http://www.eapccct.org/>
 Asia Pacific Association of Medical Toxicology—<http://www.asiattox.org/>
 South Asian Clinical Toxicology Research Collaboration—<http://www.sactrc.org/>
 TOXBASE: The primary clinical toxicology database of the National Poisons Information Service (free access for UK National Health Service hospital departments and general practices, and National Health Service departments of public health and health protection agency units; available to hospital EDs in Ireland by contract; available to European poison centers whose staff are members of the European Association of Poisons Centres and Clinical Toxicologists; overseas users may be allowed access on payment of a yearly subscription, subject to the approval of the Health Protection Agency)—<http://www.toxbase.org/>